Iran J Vet Surg, Print ISSN: 2008-3033, Online ISSN: 2676-6299

Document Type : Original Article


1 Razi Herbal Medicines Research Center, Lorestan University of medical Sciences, Khorramabad, Iran.

2 Department of Medical Chemistry, School of Pharmacy, Urmia University of Medical Sciences, Urmia, Iran

3 Department of Surgery and Diagnostic Imaging, Faculty of Veterinary Medicine, Urmia University


Objective- Breast cancer is one of the most serious problems in oncology. Alkaloids pyrrolizidine are widely found in nature and exhibited versatile biological activities. The aim of the present study was to assess anti-tumor activity of methyl 1,3-dioxo-1,1',2',3,5',6',7',7a'-octahydrospiro[indene-2,3'-pyrrolizidine]-2'-carboxylate (6) on 7,12 dimethylbenz(a) anthracene (DMBA)-induced mammary tumors in rat.
Design- Experimental study.
Animals- Twenty-one female Wistar ats
Procedures- 7-Week-old female Wistar rats (180 g body weight) were randomized into three groups of seven animals each. DMBA-induced mammary tumors was achived using DMBA dissolved in 1ml of vehicle (0.5 ml of DMSO plus 0.5 ml of saline) and injected by subcutaneous injection beneath the mammary gland on either side. Tumor yield and size were stabilized after 90 days with the initiation of DMBA. Healthy intact animals (NC) were considered as a normal control feeding on pellets and tap water. In group DMBA, the tumor was induced by DMBA. In group DMBA/7d the animals with tumor received 100 µL 6 dissolved in DMSO (0.25 µM) solution intraperitoneally for one week. Synthesis of 6 was accomplished and the structure of new product was assigned by their 1H/13C NMR, IR, CH-COSY and mass spectral data as well as the elemental analysis.
Results- The overall tumor analysis showed that 6 treatment significantly inhibited the breast tumor incidence, tumor multiplicity, and tumor size in the DMBA-initiated rat model. 6 treatment significantly inhibited the total volume of tumors per rat.
Conclusion and Clinical Relevance-The findings of the present study showed that the 6 treatment was significantly effective in reduction of tumors versus the cancer controls.


Main Subjects



One of the major diseases causing death across the world is cancer. Breast cancer is one of the most serious problems in oncology. It is a leading cause of death among women in many countries. The American Cancer Society estimates that in 2015, approximately 2, 11, 240 women are newly diagnosed with this disease and 40,410 dieannually.1

The incidence rates of breast cancer were recorded as 19,240 (29.9%) and mortality rate 5640(18.4%), as per the breast cancer facts and figures.1

Nitrogen-bridgehead fused heterocycles containing an imidazole ring are a common structural moiety in many pharmacologically important molecules that display a wide range of activities for diverse number of targets. One of the most widely used heterocyclic system from this group is imidazopyridine.2 Imidazopyridines show a spectrum of biological activities like inhibitors of aromatase estrogen production suppressors, positive inotropic agents, platelet aggregation inhibitors, thromboxane synthetase inhibitors, antiviral, antibacterial, hypnoselective and anxioselective activities.3-9 Imidazopyridines exhibit different type of molecular mechanisms in cancer chemotherapy. Recently, Wu and

coworkers reported 3,7-diarylimidazopyridinesas inhibitors of the vascular endothelial growth factor(VEGF)-receptor KDR.10 VEGF is a regulator of vascular permeability and an inducer of endothelial cell proliferation, migration, and survival. Activation of the VEGF pathway is a fundamental regulation of angiogenesis, the formation of new capillaries from established blood vessels. In molecular mechanisms, the mitogenic signal of VEGF is mediated through the receptor tyrosine kinase KDR (VEGFR-2).11 Substituted 2-(N-trifluoroacetylamino) imidazopyridines are known to arrest cell cycle at G2/M phase and induce apoptosis in SK-LU-1 human cancer cell line.12 Oxindoles are important pharmacophores that are known to enhance anticancer activity of some core molecules. Similarly, substituted E-3-(3-Indolylmethylene)-1,3-dihydroindol-2-ones are also reported as anticancer agents and induce apoptosis.13-18

Spirocyclicoxindoles are valuable synthetic intermediates and constitute the core units of many pharmacological agents and alkaloids.19 These compounds have attracted much attention from synthetic chemists due to their diverse biological activities including antimycobacterial, antitumor, antimicrobial, antibacterial, antifungal, antiviral, and local anesthetic properties.20-26 Hence, a number of synthetic routes have been developed for the preparation of these structural frameworks.27-31 1,3-Dipolar cycloaddition provides an efficient approach for the synthesis of five-member heterocycles and spiro-heterocycles, such as poly functionalized pyrrolidines, pyrazolidines and pyrrolizines, which widely occur in natural products and biologically active compounds.32-39 Although there are reports of synthesis of these substituted heterocycles, the development of synthetically important functionalized new spiro heterocyclic is still a challenge and has become a much attempted research endeavor. Spiropyrrolizidineoxindoles are important synthetic targets and several reports of such synthesesexist.40,41

It has been reported that a series of oxindole-derivedimidazo[1,5-a]pyrazines derivatives bear anticancer activity with significant cytotoxicity against a panel of 52 human cancer cell lines.21

Synthetic compounds of Octahydrospiro[indene-2,3'-pyrrolizidine]-1,3-diones derivative has been reported to possess a strong antioxidant and radical scavenge properties which inhibit the development of a series of solid tumor, ascites, and leukemic cell lines.21

In the present study a novel one-pot protocol for highly diastereo- and regioselective synthesis of some octahydrospiro[indene-2,3'-pyrrolizidine]-1,3-diones at room temperature or microwave irradiation has been reported.

To the best of our knowledge, however, there are no reports concerning anti-tumor activity of a novel synthetic compound of octahydrospiro[indene-2,3'-pyrrolizidine]-1,3-diones.

In the present study, anti-tumor activity of 6 was assessed on 7,12 dimethylbenz (a) anthracene-induced mammary tumors in rat. The assessments were based on anti-tumor activity and histopathological findings.


Materials and Methods


Chemicals and reagents


7,12-dimethylbenz(a)anthracene (DMBA) were purchased from Sigma Chemicals Co. (St. Louis, MO, USA). All other chemicals and reagents were also obtained from Aldrich (Sigma Aldrich ,St. Louis, MO, USA), Lancaster (Alfa Aesar, Johnson Matthew Company, Ward Hill, MA, USA) and were used without purification. Reagents were of research grade and stored at 4 °C for further use.




General procedure for the synthesis of Methyl 2'-Methyl-1,3-dioxo-1,1',2',3,5',6',7','-octahydrospiro[indene-2,3'-pyrrolizidine]-2' carboxylate (6) (0.269 g)


A Typical Procedure for Synthesis of 6 was performed under Microwave Irradiation. In brief, In an erlenmeyer flask (50 mL), a solution of ninhydrin (0.178 g, 1 mmol), proline (0.115 g, 1 mmol) and methyl methacrylate (0.105, 1 mmol) in absolute ethanol (8 mL) was prepared. The flask was irradiated in a microwave oven (800 W) for 2 min. In a meanwhile of irradiation, the reaction was boiled and CO2 gas was vigorously evolved. As the previous section, the liberation of CO2gas should be considered. TLC was monitored the progress of the reaction. After completion of the reaction, the solvent was evaporated under reduced pressure to afford green crystals of (Methyl 2'-Methyl-1,3-dioxo-1,1',2',3,5',6',7','-octahydrospiro[indene-2,3'-pyrrolizidine]-2'carbo-xylate (6) (Fig. 1, Table 1).

Spectral data for product 6 is as follow:

Methyl 2'-Methyl-1,3-dioxo-1,1',2',3,5',6',7','-octahydrospiro[indene-2,3'-pyrrolizidine]-2' carboxylate (6): Yellow prism (EtOH), 88–91% yield, m.p. 111–112 ˚C. 1H NMR (CDCl3, 500 MHz) δ 1.67 (3H, s, CH3), 1.68-1.78 (1H, m, 7'-CH), 1.83-1.93 (1H, m, 7'-CH), 1.94-2.03 (2H, m, 6'-CH2), 2.06 (1H, dd,  J = 6.2, 12.2 Hz, 1'-CH), 2.43-2.48 (1H, m, 1'-CH), 2.71-2.76 (2H, m, 5'-CH2),  3.29 (3H, s, OCH3), 3.95-4.04 (1H, m, 'α-H), 7.83-7.92 (3H, m, ArH), 8.01-8.03 (1H, m, ArH). 13C NMR (CDCl3, 125 MHz) δ 14.26 (CH3), 29.21, 31.21, 33.65, 48.84, 51.91 (OCH3), 55.17, 68.35 (Cspiro), 74.12 (CH-N), 122.12, 123.91, 136.24 (4CH, aromatic), 142.17, 142.22 (2Cipso, aromatic), 171.29, 203.40, 204.71 (3C=O). IR (υmax/cm-1, KBr) 1680, 1584 (2C=O). MS (m/e, %) 313 (M+, 75), 254 (M+-CO2Me, 30), 212 (254-C3H6, 100), Anal. calcd for C18H19NO4 (313.348): C, 68.99; H, 6.11; N, 4.47; O, 20.42%. Found: C, 68.98; H, 6.16; N, 4.48; O, 20.42%.


Ethical statement


This study was carried out in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. The protocol was approved by the Ethical Committee of Urmia University of Medical Sciences.


Animals, study design, and tumor induction and inhibition study


7-Week-old female Wistar rats (100 g body weight) were randomized into three groups of seven animals each. They were maintained at 28±1 C, relative humidity 60 °C (12-hlight and 12-h dark cycle), and provided with standard food pellets (diet composition, wheat broken—moisture9.0%, crude protein 11.5%, crude fat 1.9%, crude fibre4.0%, Ash 0.2%, nitrogen-free extract 73.4%) and tap water ad libitum. DMBA-induced mammary tumors was adopted based on a method described by others with slight modifications.42,43 DMBA was dissolved in 1ml of vehicle (0.5 ml of DMSO plus 0.5 ml of saline) and injected by subcutaneous injection beneath the mammary gland on either side. Tumor yield and size were stabilized after 90 days with the initiation of DMBA, and these served as breast cancer control animals without any treatment. The effect of 6 on DMBA-induced tumors was determined after 90 days in the promotional stage of tumor development. Healthy intact animals (NC) were considered as a normal control feeding on pellets and tap water. In group DMBA, the tumor was induced by DMBA. In group DMBA/6 the animals with tumor received 100 µL 6 dissolved in DMSO (0.25 µM) solution interaperitoneally for one week. The experimental rats were regularly monitored for food and water consumption, the apparent signs of toxicity, weight loss, or mortality. The tumor incidence and its multiplicity were also recorded either at the time when carcinoma-bearing rats died, or at the termination of the experiment. After 110 days, all the animals were starved overnight and sacrificed by cervical decapitation. The breast tumor was surgically dissected out, tumor volumes (mm in diameter) of both cancer controls, as well as the experimental groups were measured, and total body weight (g) also recorded based on a method described by others.44


Histopathological examination


Macroscopic mammary tumors, fixed in 10%buffered formalin, were embedded in paraffin using a conventional automated system. The blocks were cut to obtain 5µm thick sections and stained with hematoxylin–eosin. Serial paraffin sections of each tissue image were captured by light microscopy.


Statistical analysis


Statistical comparisons between control and treatment mean values of two parameters were analyzed using the Student’s t-test. Multiple comparisons were done using ANOVA. The differences were statistically significant atP < 0.05.






The results obviously indicated that using microwaves dramatically increased the inter-collusion of molecules as well as the temperature of reaction to afford higher rate enhancement. All products were assigned by their 1H and 13C NMR, FTIR, CH-COSY, MS and elemental analysis.

The C-H correlation for adduct 6 again confirmed high regioselectivity of the reaction pattern. (Fig. 2)

Anti-tumor activity


Tumor promotional stage is a reversible stage in the multistage carcinogenesis; therefore, it is the most suitable stage for the anti-carcinogenic agent to prevent, reverse, or slow down the process of carcinogenesis. Animals in the DMBA group attained a promotional stage tumor after 90 days. At the end of the experiment in animal of DMBA group, DMBA-induced breast tumors were increased to the maximum in terms of tumor incidence (100%), tumor multiplicity per rat, and tumor weight (52%) compared to the normal control rats (NC group) (P<0.05). The animals that administered 6 achieved 52% of tumor reduction after 20days treatment. Tumor weight analysis also revealed statistically significant reduction of breast tumor weight in 6 treated groups when compared to the cancer controls (DMBA group). The tumor data analyzed in terms of tumor multiplicity recorded, in the DMBA animals, a 39 mm breast tumor size compared to 6treated rats that showed 33 mm breast tumor size (Fig 3). The overall tumor analysis showed that 6 treatment significantly inhibited the breast tumor incidence, tumor multiplicity, and tumor size in the DMBA-initiated rat model (Table 2).

Histopathological examination


The combination 6 treated group showed tumor nodules and formation of intra-tumor vascularization. The vast majority of the lesions that developed in the rat mammary glands were mostly carcinomas. Inflammatory cell infiltration was absent in carcinomas. Most carcinomas exhibited a mixed structural pattern, with invasion of neighboring tissues, and intense stromal desmoplastic reaction. Histopathology, it was revealed that most carcinomas exhibited an identical nuclear pattern. Most tumors were predominantly epithelial with fibrous tissue surrounding the mammary ducts (Fig 4).



Animal experimental systems are particularly useful for the study of human mammary carcinogenesis. The mammary gland is one of the few organs that are not totally developed at birth. It undergoes intense evolutive and functional modifications during puberty, pregnancy, and lactation. Others have described the developmental progression of human breast tissue and listed 4 different types of breast lobules.45 Type 1 (or virginal) is the most undifferentiated lobule and occurs in the immature female breast before menarche. Type 2 lobule has a more complex morphology, being composed by a higher number of ductular structures per lobule. Type 3 has an average of 80 alveoli (ductules) and is formed under gestational hormonal stimulation. Type 4 is a secreting lobule during lactation. The mammary tumors in rats arise in the epithelium of the terminal end buds, which are comparable structures to the terminal ductal lobular units in the human breast.46 The degree of lobular differentiations of importance in the susceptibility to carcinogenesis. Based on studies of the pathogenesis of human mammary cancer, it is possible to say that the type 1 lobule is the site of origin of preneoplastic lesions. Parous women undergo lobular differentiation, whereas nulliparous women seldom reach the type 3 lobule stage. The breasts of parous women free of cancer have the lowest percentage of type1 lobules. Lobules type 1 and 2 are characterized by having a shorter doubling time than type 3, growing faster and having a higher DNA labeling index. The susceptibility of the mammary gland to DMBA carcinogenesis is strongly age-dependent, being maximal when the drug is administered to rats between the ages of 45 and 60days, which is the age of the beginning of sexual maturity.46 Active breast organogenesis and high rate of proliferation of type 1 and 2 lobules are characteristics of that period. The chance of chemically inducing breast cancer in rats is greater if DMBA is administered in this phase of the life of the animals. This was the reason why we injected the drug at the age of 47 days. According to the literature, the induced tumors are generally ductal carcinomas or papillary carcinomas, but it is possible that typical fibroadenomas, adenomas, and papilloma as are also formed.47Epithelial and myoepithelial cell proliferation were observed in most of the induced tumors in our experiment. Russo et al. found the same histological aspects. They also carefully presented the correlation between neoplastic and non-neoplastic alterations in the mammary gland of rats and in women.11 Most of the lesions found in rats have corresponding lesions in humans, allowing the translation of basic research in rats into the clinic.48

The induced DMBA tumors in this study were multifocal and locally aggressive, but no single case of metastases was identified. This fact is in agreement with studies done by other authors, and metastasis from even the most anaplastic induced tumors are low in frequency.49The absence of metastases in chemically produced mammary neoplasms opens the door for speculation.

The proliferation of epithelial and myoepithelial cells in relatively equal proportions may be a protective factor against metastasis.47In human breast carcinomas, proliferation occurs almost exclusively in epithelial cells. DMBA is highly lipophilic and requires metabolic activation for its carcinogenicity. Several tissues are capable of activating DMBA, and these include the mammary gland. In the breast, DMBA is converted to epoxides, active metabolites with a capacity for damaging the DNA molecule, the main event in carcinogenesis initiation. With the higher cellular proliferative index of types 1 and 2 lobules, there is higher metabolic activity and more epoxide formation.50,51

Since the rat mammary gland shows a high susceptibility to developing neoplasms which closely mimic human breast cancer, they have been selected in comparison to other animal models.52

In the present investigation, treatment with 6 exhibited potential anticancer activity on DMBA-induced mammary tumors in rats. As a result, the body weight had also slightly increased, the tumor volume decreased, and the percentage of tumor inhibition was statistically significant (P < 0.05).

The histopathological examination revealed that most carcinomas exhibited a mixed structural

pattern such as nodular well, invasion of neighboring tissues, with intense stromal desmoplastic reaction and necrosis. Upon correlating the histopathological examination, it was evident that most carcinomas exhibited identical nuclear patterns. The tumors were predominantly epithelial, and fibrous tissue surrounded the mammary ducts.6 treatment significantly inhibited the total volume of tumors per rat. The supply of blood to newly forming tissues and to tumors is a limiting factor that regulates growth.53 The process of neovascularization provides blood to supportangiogenesis.53 This observation suggests that vascularization could be helpful in explaining in differential effects of cancer preventive agents on angiogenesis in the intra-tumoral region.

The findings of the present study showed that the 6 treatment was significantly effective in reduction of tumors versus the cancer controls. This experimental animal mode closely mimics human breast cancer and can be used as a comparative group in further studies with the purpose of elucidating the role of novel synthetic agents in mammary carcinogenesis. The effects of pretreatment and post treatment of rats with other similar substances that have action on mammary carcinogenesis will be the endpoints of future research in our laboratory using this animal model.




This study was a part of thesis in partial fulfilment of Doctor of Pharmacy at School of Pharmacy, Urmia University of Medical Sciences. Authors would like to acknowledge the school for support of this study.


Conflicts of interests


  1. DeSantis CE, Fedewa SA, Goding Sauer A, Kramer JL, Smith RA, Jemal A. Breast cancer statistics, 2015: Convergence of incidence rates between black and white women. CA: A Cancer Journal for Clinicians, 2016;66(1):31-42.
  2. Humphries AC, Gancia E, Gilligan MT, Goodacre S, Hallett D, Merchant KJ, Thomas SR. 8-Fluoroimidazo[1,2-a] pyridine: synthesis, physicochemical properties and evaluation as a bioisosteric replacement for imidazo [1,2-a]pyrimidine in an allosteric modulator ligand of the GABA A receptor. Bioorganic & Medicinal Chemistry Letters, 2006;16(6):1518-22.
  3. Browne LJ, Gude C, Rodriguez H, Steele RE, Bhatnager A. Fadrozole hydrochloride: a potent, selective, nonsteroidal inhibitor of aromatase for the treatment of estrogen-dependent disease. Journal of Medicinal Chemistry, 1991;34(2):725-36.
  4. Davey D, Erhardt PW, Lumma WC Jr, Wiggins J, Sullivan M, Pang D, Cantor E. Cardiotonic agents. 1. Novel 8-aryl-substituted imidazo [1,2-a]- and -[1,5-a] pyridines and imidazo [1,5-a] pyridinones as potential positive inotropic agents. Journal of Medicinal Chemistry, 1987;30(8):1337-42.
  5. Ford NF, Browne LJ, Campbell T, Gemenden C, Goldstein R, Gude C, Wasley JW. Imidazo[1,5-a] pyridines: a new class of thromboxane A2 synthetase inhibitors. Journal of Medicinal Chemistry,1985;28(2):164-70.
  6. Hamdouchi C, Sanchez-Martinez C, Gruber J, Del Prado M, Lopez J, Rubio A, Heinz BA. Imidazo[1,2-b] pyridazines, novel nucleus with potent and broad spectrum activity against human picornaviruses: design, synthesis, and biological evaluation. Journal of Medicinal Chemistry, 2003;46(20):4333-41.
  7. Krause M, Foks H, Gobis K. Pharmacological Potential and Synthetic Approaches of Imidazo[4,5-b]pyridine and Imidazo[4,5-c]pyridine Derivatives. Molecules. 2017;22(3).
  8. Mavel S, Renou JL, Galtier C, Snoeck R, Andrei G, Balzarini J, De Clercq E, Gueiffier A. Synthesis of imidazo[1,2-a]pyridine derivatives as antiviral agents. Arzneimittel-Forschung journal, 2001;51(4):304-9.
  9. Greenblatt DJ, Roth T. Zolpidem for insomnia. Expert Opinion on Pharmacotherapy, 2012;13(6):879-93.
  10. Wu Z, Fraley ME, Bilodeau MT, Kaufman ML, Tasber ES, Balitza AE, Hartman GD, Coll KE, Rickert K, Shipman J, Shi B, Sepp-Lorenzino L, Thomas KA.  Design and synthesis of 3,7-diarylimidazopyridines as inhibitors of the VEGF-receptor KDR. Bioorganic & Medicinal Chemistry Letters, 2004;14(4):909-12.
  11. Vilchis-Reyes MA, Zentella A, Martínez-Urbina MA, Guzmán A, Vargas O, RamírezApan MT, Ventura Gallegos JL, Díaz E. Synthesis and cytotoxic activity of 2-methylimidazo[1,2-a]pyridine- and quinoline-substituted 2-aminopyrimidine derivatives. European Journal of Medicinal Chemistry, 2010;45(1):379-86.
  12. Mukherjee A1, Dutta S, Sanyal U. Evaluation of dimethoxydop-NU as a novel anti-tumor agent. Journal of Experimental and Clinical Cancer Research, 2007;26(4):489-97.
  13. Samanta S, Pain A, Dutta S, Saxena AK, Shanmugavel M, Pandita RM, Qazi GN, Sanyal U. Antitumor activity of Nitronaphthal-NU, a novel mixed-function agent. Journal of Experimental Therapeutics & Oncology,2005;5(1):15-22.
  14. Andreani A, Burnelli S, Granaiola M, Leoni A, Locatelli A, Morigi R, Rambaldi M, Varoli L, Kunkel MW. Antitumor activity of substituted E-3(3,4,5trimethoxybenzylidene)-1,3-dihydroindol-2-ones1. Journal of Medicinal Chemistry, 2006;49(23):6922-4.
  15. Andreani A, Granaiola M, Leoni A, Locatelli A, Morigi R, Rambaldi M, Garaliene V, Farruggia G, Masotti L. Substituted E-3-(2-Chloro-3-indolylmethylene)1,3-dihydroindol-2-ones with antitumor activity. Bioorganic & Medicinal Chemistry Letters, 2004;12(5):1121-8.
  16. Andreani A, Burnelli S, Granaiola M, Leoni A, Locatelli A, Morigi R, Rambaldi M, Varoli L, Calonghi N, Cappadone C, Farruggia G, Zini M, Stefanelli C, Masotti L. Substituted E-3-(2-chloro-3-indolylmethylene)1,3-dihydroindol-2-ones with antitumor activity. Effect on the cell cycle and apoptosis. Journal of Medicinal Chemistry, 2007;50(14):3167-72.
  17. Leoni A, Locatelli A, Morigi R, Rambaldi M, Cappadone C, Farruggia G, Iotti S, Merolle L, Zini M, Stefanelli C. Substituted E-3-(3-indolylmethylene)1,3-dihydroindol-2-ones with antiproliferative activity. Study of the effects on HL-60 leukemia cells. European Journal of Medicinal Chemistry, 2014;79:382-90.
  18. Marti C, Carreira EM. Construction of spiro[pyrrolidine-3,3-oxindoles]-recent applications to the synthesis of oxindole alkaloids. European Journal of Organic Chemistry, 2003;2003:2209-2219.
  19. Prasanna P, Balamurugan K, Perumal S, Yogeeswari P, Sriram D. A regio- and stereoselective 1,3-dipolar cycloaddition for the synthesis of novel spiropyrrolothiazolyloxindoles and their antitubercular evaluation. European Journal of Medicinal Chemistry, 2010;45:5653-5661.
  20. Kamal A, Ramakrishna, Raju P, Rao AV, Viswanath A, Nayak VL, Ramakrishna S. Synthesis and anticancer activity of oxindole derived imidazo[1,5 a]pyrazines. European Journal of Medicinal Chemistry,  2011;46:2427-2435.
  21. Periyasami G, Raghunathan R, Surendiran G, Mathivanan N. Synthesis of novel spiropyrrolizidines as potent antimicrobial agents for human and plant pathogens. Bioorganic & Medicinal Chemistry Letters, 2008;18:2342-23425.
  22. Mhaske PC, Shelke SH, Jadhav RP, Raundal HN, Patil SV, Patil AA, Bobade VD. Synthesis, characterization, and antimicrobial activity of 3′-(4-(2-substituted thiazol-4-yl) phenyl) spiro [indoline-3,2′-thiazolidine]-2,4′-diones. J. Heterocyclic Chem. 2010;47: 1415-1420.
  23. ThangamaniA. Regiospecific synthesis and biological evaluation of spiro oxindolo pyrrolizidines via [3+2] cycloaddition of azomethineylide. European Journal of Medicinal Chemistry, 2010;45:6120-6126.
  24. Jiang T, Kuhen KL, Wolff K, Yin H, Bieza K, Caldwell J, Bursulaya B,Tuntland T, Zhang K, Karanewsky D, He Y. Design, synthesis, and biological evaluations of novel oxindoles as HIV-1 non-nucleoside reverse transcriptase inhibitors. Part 2. Bioorganic & Medicinal Chemistry Letters, 2006;16:2109-2112.
  25. Kornet MJ, Thio AP. Oxindole-3-spiropyrrolidines and piperidines. Synthesis and local anesthetic activity. Journal of Medicinal Chemistry, 1976;19:892-898.
  26. Miyamoto H, Okawa Y, Nakazaki A, Kobayashi S. Highly diastereoselective one-pot synthesis of spirocyclicoxindoles through intramolecularUllmann coupling and Claisen rearrangement. Angewandte Chemie International Edition, 2006;45:2274-2277.
  27. Basavaiah D, Reddy KR. Simple and one-pot protocol for synthesis of indene-spiro-oxindoles involving tandem Prins and Friedel-Crafts reactions. Organic Letters, 2007;9:57-60.
  28. Bencivenni G, Wu LY, Mazzanti A, Giannichi B, Pesciaioli F, Song MP, Bartoli G, Melchiorre P. Targeting structural and stereochemical complexity by organocascade catalysis: Construction of spirocyclicoxindoles having multiple stereocenters. Angewandte Chemie International Edition, 2009;48:200-7203.
  29. Shanthi G, Perumal PT. An efficient one-pot synthesis of novel pyrazolophthalazinylspirooxindoles. Journal of Chemical Sciences, 2010;122:415-421.
  30. Hazra A, Paira P, Sahu KB,  Naskar S, Saha P, Paira R, Mondal S, Maity A, Luger P, Weber M, Mondal NB, Banerjee S. Chemistry of andrographolide: formation of novel di-spiropyrrolidino and di-spiropyrrolizidino-oxindole adducts via one-pot three-component [3+2] azomethineylide cycloaddition. Tetrahedron Letters, 2010;51:1585-1588.
  31. Gomes PJS, Nunes CM, Pais AACC, Pinho e Melo TMVD, Arnaut LG. 1,3-Dipolar cycloaddition of azomethineylides generated from aziridines in supercritical carbon dioxide. Tetrahedron Letters, 2006;47:5475-5479.
  32. Grigg R, Sarker MAB. XY-ZH compounds as potential 1,3-dipoles. Part 63: Silver catalyzed azomethineylidecycloaddition-the synthesis of spirohomoserine lactone analogues. Tetrahedron Letters,  2006;62:10332-10343.
  33. Watson AA, Fleet GWJ, Asano N, Molyneux RJ, Nash RJ. Polyhydroxylatedalkaloidsnatural occurrence and therapeutic applications. Phytochemistry,  2001;56:265-295.
  34. ShanmugamP,Viswambharan B, Madhavan S. Synthesis of novel functionalized 3 spiropyrrolizidine and 3-spiropyrrolidine oxindoles from Baylis-Hillman adducts of isatin and heteroaldehydes with azomethineylides via [3+2] cycloaddition. Organic Letters, 2007;9: 4095-4098.
  35. Yu J, He L, Chen XH, Song J, Chen WJ, Gong LZ. Highly enantioselective catalytic 1,3-dipolar cycloaddition involving 2,3-allenoate dipolarophiles. Organic Letters, 2009;11:4946-4949.
  36. Cheng MN, Wang H, Gong LZ. Asymmeticorganocatalytic 1,3-dipolar cycloaddition of azomethineylide to methyl 2-(2-nitrophenyl)acrylate for the synthesis of diastereoisomers of spirotryprostatin A. Organic Letters, 2011:13:2418-2421.
  37. Michael JP. Indolizidine and quinolizidine alkaloids. Nat. Prod. Rep. 1997;14:619-636.
  38. Liddell JR. Pyrrolizidine alkaloids. Natural Product Reports,1998;15:363-370.
  39. Rehn S, Bergman J, Stensland B. The three-component reaction between isatin, α-amino acids, and dipolarophiles. European Journal of Organic Chemistry, 2004;2004:413-418.
  40. Prasanna R, Purushothaman S, Raghunathan R. Highly regioselective synthesis of glycospiro heterocycles through 1,3-dipolar cycloaddition reaction. Tetrahedron Letters, 2010;51:4538-4542.
  41. C. Huggins LC, Grand FP, Brillantes, Mammary cancer induced by a single feeding of polynuclear hydrocarbons, and its suppression. Nature, 1961;198:204–207.
  42. CostaI, SolanasM, EscrichE. Histopathologic characterization of mammary neoplastic lesions induced with 7,12- dimethylbenz(a)anthracene in the rat. A comparative analysis with human breast tumor.Archives of Pathology & Laboratory Medicine, 2002;126:915–927.
  43. Samy RP, Gopalakrishnakone P, Ignacimuthu S. Anti-tumor promoting potential of luteolin against 7,12-dimethylbenz(a)anthracene-induced mammary tumors in rats. Chemico-Biological Interactions, 2006;164(1-2):1-14.
  44. Russo J, Russo IH. Toward a physiological approach to breast cancer prevention. Cancer Epidemiol Biomarkers Prev, 1994;3:353-64.
  45. Grubbs CJ, Juliana MM, Hill DL, Whitaker LM. Suppression by pregnancy of chemically induced preneoplastic cells of the rat mammary gland. Anticancer Research, 1986;6:2395-401.
  46. Murad TM, von Haam E. Studies on mammary carcinoma induced by 7,12-dimethylbenzanthracene administration. Cancer Research, 1972;32:1404-15.
  47. Clarke R. Animal models of breast cancer: experimental design and their use in nutrition and psychosocial research. Breast Cancer Research and Treatment,1997;46:117-33.
  48. Russo J, Gusterson BA, Rogers AE, Russo IH, Wellings SR, van Zwieten MJ.. comparative study of human and rat mammary tumorigenesis. Lab Invest 1990;62:244-77.
  49. Russo J, Larref MH, Balogh G, Balogh G, Guo S, Russo IH. Estrogen and its metabolites are carcinogenic agents in human breast epithelial cells. Journal of Steroid Biochemistry and Molecular Biology,2003;37:1-25.
  50. Balogh GA, Russo IH, Russo J. Mutations in mismatch repairs genes are involved in te neoplastic transformation of human breast epithelial cells. International Journal of Oncology, 2003;23:411-9.
  51. Flohe L, Otting F. Superoxide dismutase assays.Methods in Enzymology, 1984;105- 93.
  52. Folkman J, D’Amore PA. Blood vessel formation: what is the molecular basis? Cell 1996;87:1153–1155.
  53. Folkman J, Watson K, Ingber D, Hanahan D. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature, 1989;339:58–61.